Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Augmenting Standard Rehabilitation With Blood Flow Restriction for Chronic Achilles Tendinopathy

9 de julio de 2026 actualizado por: Mariam ibrahim, Assiut University

Augmenting Standard Rehabilitation With Blood Flow Restriction for Chronic Achilles Tendinopathy: Randomized Clinical Control Trial

Chronic insertional Achilles tendinopathy is a common overuse condition that can be slow to improve with traditional loading-based rehab (e.g., eccentric loading, activity modification, graded return to function). Outcomes are often variable, and persistent symptoms can limit how much load patients can tolerate early in rehab.

This outpatient randomized controlled trial will compare standard-of-care rehabilitation alone versus standard-of-care rehabilitation plus blood flow restriction (BFR) training in adults with chronic insertional Achilles tendinopathy. BFR uses an external cuff to partially restrict blood flow during low-load resistance exercise, aiming to produce strength and hypertrophy adaptations with less mechanical stress than high-load training. Evidence supporting BFR's physiologic effects and safety in musculoskeletal rehab is summarized in clinical research literature.

Participants will be randomized (stratified by baseline activity level and symptom severity) to receive the same rehab program, with the experimental group performing strengthening with BFR using Smart Tools Plus cuffs applied at the proximal thigh and set to 40-80% limb occlusion pressure. The primary outcome will be the VISA-A score (a validated measure of Achilles tendinopathy severity), with secondary outcomes including pain ratings, functional performance tests (e.g., single-leg heel raise endurance, hopping/time-to fatigue), and calf strength via handheld dynamometry.

Descripción general del estudio

Descripción detallada

Chronic insertional Achilles tendinopathy is an overuse condition with prolonged recovery, where outcomes after traditional loading programs can be variable. Your protocol builds on standard rehabilitation principles (progressive loading, symptom-guided activity modification, and graded return to function) while testing whether blood flow restriction (BFR) can improve rehabilitation efficiency by enabling meaningful neuromuscular adaptation at lower external loads. This rationale aligns with emerging mechanistic and clinical evidence that low-load BFR can drive clinically relevant adaptations while reducing mechanical stress on painful tissues.

This study is designed as a two-arm randomized controlled trial conducted in an outpatient rehabilitation setting, comparing standard-of-care rehabilitation alone versus standard-of-care rehabilitation augmented with BFR. The overarching hypothesis is that adding BFR to a structured rehabilitation pathway will yield superior improvements in pain-related disability and function (tracked with validated clinical instruments) and will translate into better performance on functional tasks commonly affected in Achilles tendinopathy (e.g., endurance and hopping tolerance).

To ensure diagnostic precision and a clinically homogeneous sample, the protocol specifies confirmation of chronic insertional Achilles tendinopathy using a combination of symptom chronicity and exam/imaging features, including localized tenderness near the calcaneal insertion, functional provocation testing, and imaging evidence of structural tendon change (ultrasound or MRI). These steps are intended to reduce misclassification and improve interpretability of treatment effects in a condition with multiple pain generators around the posterior heel.

Randomization is structured to enhance baseline balance on variables that can meaningfully influence rehabilitation response. Specifically, allocation is stratified by baseline activity level (Cincinnati Sports Activity Scale) and by baseline clinical severity using a VISA-A threshold (<50 vs ≥50). The target sample size is 40 participants (20 per group), selected to detect a clinically meaningful improvement on the VISA-A (minimal clinically important difference of 10 points) with 90% power and α=0.05, while incorporating an allowance for attrition. The analysis plan is aligned with CONSORT expectations for rehabilitation trials and anticipates covariate-adjusted mixed modeling to evaluate group-by-time effects.

Intervention delivery follows a pragmatic rehabilitation model. The standard-care arm uses established physical therapy approaches-progressive loading (including eccentric-focused strategies), education on activity modification, and a staged return-to-function progression-implemented and advanced based on symptoms and functional tolerance. In the BFR-augmented arm, the same rehabilitation exercises are performed while applying BFR using Smart Tools Plus (LLC, USA) with limb sleeves and cuffs placed proximally on the thigh. Limb occlusion pressure (LOP) is set individually immediately prior to exercise, and the protocol applies 40-80% of LOP during the exercise sets. Participants are monitored throughout for adverse signs/symptoms, consistent with published evidence that BFR-when appropriately screened, dosed, and supervised-has an acceptable safety profile in musculoskeletal rehabilitation populations.

Outcomes are captured longitudinally across baseline and follow-up timepoints and include a patient-reported measure of Achilles tendinopathy severity (VISA-A) and functional performance metrics (e.g., single-leg heel raise endurance, hopping tolerance/time to fatigue), alongside quantification of plantarflexor/calf strength using handheld dynamometry. The VISA-A is a widely used index with published reliability and construct validity for grading clinical severity in Achilles tendinopathy research.

Data will be evaluated using repeated-measures modeling to compare within-group change over time and between-group differences in trajectories, with covariate adjustment consistent with the stratification variables and planned mixed-model approach. Results will be reported at the group level and interpreted in relation to clinically meaningful change thresholds, with the goal of informing whether BFR is a practical and scalable adjunct to standard rehabilitation for chronic insertional Achilles tendinopathy-especially for patients who cannot tolerate higher external loads early in the rehabilitation process.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

80

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Asyut, Egipto
        • Faculty of medicine, Assiut university

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Age 18-65 years
  • Chronic insertional Achilles tendinopathy (symptoms >3 months but <3 years)
  • VISA-A score <80
  • Confirmed diagnosis via:
  • Palpation pain within 2 cm of calcaneal insertion
  • Positive single leg-hop test
  • Ultrasound or MRI evidence of structural tendon changes (hypoechoic areas, thickening, or Doppler flow)
  • No prior BFR training as part of rehab within the last 3 months

Exclusion Criteria:

  • Inability to give informed consent
  • Uncontrolled blood pressure (>160/100 mmHg)
  • Uncontrolled diabetes
  • Familial hypercholesterolemia
  • History of deep vein thrombosis
  • History of blood clots
  • Hypercoagulable states
  • Cancer
  • Active infection
  • History of sickle cell anemia
  • Peripheral vascular disease
  • Morbid obesity (BMI >40)
  • End-stage renal disease requiring dialysis
  • Alcohol use disorder / alcohol abuse
  • Claustrophobia
  • Pregnant woman
  • Inability to follow study protocol (e.g., cannot attend visits or comprehend instructions)
  • Psychiatric illness preventing comprehension or interfering with follow up
  • Lymphadenectomy
  • Any clinical finding that places the patient at health risk, impacts the study, or affects completion
  • History of Achilles tendon rupture or surgery
  • Concurrent midportion Achilles tendinopathy or other ankle pathology (e.g., arthritis)
  • Recent treatments within the past 3 months: physiotherapy, local injections, shockwave therapy, orthotic use

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Standard Rehabilitation
Participants receive standard-of-care rehabilitation for chronic insertional Achilles tendinopathy, including eccentric loading, activity modification, and gradual return to function
Participants complete a standardized outpatient rehabilitation program for chronic insertional Achilles tendinopathy. Standard care includes progressive tendon/calf loading using an eccentric-loading emphasis, education and symptom-guided activity modification, and a graded return-to-function progression. The program is delivered under physical therapy supervision using standard exercise tools, with progression based on participant tolerance and clinical response.
Experimental: Standard Rehabilitation + Blood Flow Restriction (BFR)
Participants receive the same standard-of-care rehabilitation plus blood flow restriction (BFR) training applied during exercise sets using Smart Tools Plus (LLC, USA) cuffs placed on the proximal thigh with a protective sleeve. Limb occlusion pressure (LOP) is set individually at 40-80% immediately before exercise and applied during the entire exercise set.
Participants complete a standardized outpatient rehabilitation program for chronic insertional Achilles tendinopathy. Standard care includes progressive tendon/calf loading using an eccentric-loading emphasis, education and symptom-guided activity modification, and a graded return-to-function progression. The program is delivered under physical therapy supervision using standard exercise tools, with progression based on participant tolerance and clinical response.
Blood flow restriction (BFR) is applied during low-load resistance exercise using Smart Tools Plus cuffs and limb sleeves. The sleeve is used to protect the skin/soft tissue beneath the cuff, and the cuff is placed around the proximal thigh (right and left as applicable). Individual limb occlusion pressure (LOP) is determined immediately prior to exercise; cuff pressure is set to 40%-80% of LOP and maintained during the entire exercise set. Participants are monitored during BFR application for adverse signs/symptoms (e.g., excessive pain, numbness/paresthesia, abnormal discoloration), and BFR is stopped if safety concerns arise.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
VISA-A (Victorian Institute of Sport Assessment-Achilles) Score
Periodo de tiempo: Baseline (pre-intervention) and Week 8 (end of intervention period)
Description: Patient-reported outcome assessing Achilles tendinopathy severity; total score ranges 0-100 with higher scores indicating fewer symptoms/better function. This tool is validated for Achilles tendinopathy and commonly used in research/clinical settings.
Baseline (pre-intervention) and Week 8 (end of intervention period)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Pain Rating (Numeric Pain Rating Scale or Visual Analog Scale)
Periodo de tiempo: Baseline (pre-intervention) and Week 8 (end of intervention period)
Self-reported pain intensity (e.g., NPRS 0-10 or VAS), where higher scores indicate worse pain.
Baseline (pre-intervention) and Week 8 (end of intervention period)
Single-Leg Heel Raise Endurance Test
Periodo de tiempo: Baseline (pre-intervention) and Week 8 (end of intervention period)
Functional performance/endurance measure recorded as repetitions to fatigue (or a pre-specified stopping criterion such as pain limit/technique failure).
Baseline (pre-intervention) and Week 8 (end of intervention period)
Hopping Test (or Time-to-Fatigue Hopping Test)
Periodo de tiempo: Baseline (pre-intervention) and Week 8 (end of intervention period)
Functional performance test recorded as time to fatigue and/or maximum hops completed using a standardized protocol.
Baseline (pre-intervention) and Week 8 (end of intervention period)
Calf Muscle Strength (Handheld Dynamometry)
Periodo de tiempo: Baseline (pre-intervention) and Week 8 (end of intervention period)
Peak force (or average peak across trials) measured with a handheld dynamometer using a standardized position and lever arm; reported in Newtons (N) or kilograms-force (kgf), depending on device settings.
Baseline (pre-intervention) and Week 8 (end of intervention period)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de agosto de 2025

Finalización primaria (Estimado)

30 de junio de 2026

Finalización del estudio (Estimado)

30 de septiembre de 2026

Fechas de registro del estudio

Enviado por primera vez

8 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

9 de julio de 2026

Publicado por primera vez (Actual)

13 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de julio de 2026

Última verificación

1 de febrero de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 04-2025-300683

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir